All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 151 of 206 pages ‹ First < 149 150 151 152 153 > Last ›
HSL1234
Carter T.
Pfizer and its competitive marketing challenges.
J Hosp Mark Public Relations 2003;14:(2):85-97
HSL1237
Bozik M.
He who pays the piper calls the tune: the role of the industry sponsor in acute stroke trials.
Eur Neurol 2003;49:(2):128-30
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=ENE49128
HSL1239
Bonnemain B.
[When blood and meat were drugs]
Rev Hist Pharm (Paris).2003;51(340):611-24 2003;51:(340):611-24
HSL1240
Bond C, Hannaford P.
Issues related to monitoring the safety of over-the-counter (OTC) medicines.
Drug Saf 2003;26:(15):1065-74
HSL1246
Baker E, Newnes C, Myatt H.
Drug companies and clinical psychology.
Ethical Hum Sci Serv 2003 Fal;5:(3):247-53
HSL1400
Hargreaves I.
Towards a better map: Science, the public and the media
Economic and Social Research Council (ESRC), 2003
http://web.archive.org/web/20040804071704/http://www.esrc.ac.uk/esrccontent/downloaddocs/Mapdocfinal.pdf
HSL1820
Chen P; Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, NY, USA.
Education or promotion?: Industry-sponsored continuing medical education (CME) as a center for the core/commercial speech debate
Food Drug Law J. 2003;58:(3):473-509
HSL1900
Shah S.
Globalization of clinical research by the pharmaceutical industry.
Int J Health Serv 2003;33:(1):29-36
HSL1904
Radinsky G.
The spotlight on PBMs: federal enforcement of the anti-kickback statute on the pharmaceutical benefit management industry.
J Health Law 2003 Spr;36:(2):213-46
HSL1905
Potts M.
Two pills, two paths: a tale of gender bias.
Endeavour 2003;27:(3):127-30
HSL1910
Motchane JL.
Health for all or riches for some: WHO's responsible?
Int J Health Serv 2003;33:(2):395-400
HSL2044
Kay J.
The Truth about Markets: Why Some Nations are Rich but Most Remain Poor
London: Penguin Books 2003
http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html
HSL2235
Malugani M.
Want a Future in Pharmaceutical Sales?
2003
http://healthcare.monster.com/pharm/articles/pharmsales/
HSL2281
Hubbard R, Bayarri MJ.
Confusion over measures of evidence versus errors in classical statistical testing.
Am Statistician 2003;57:171-182
HSL3692
Health Canada.
Health Protection Legislation. Detailed Legislative Proposal.
Ottawa: Health Canada. 2003
http://www2.itssti.hc-sc.gc.ca/HPCB/Policy/LegislativeRenewal.nsf/fb7c4e1fc0e11e1c85256d24006a12e5/b89331835ada362b85256d3d004f10f3/$FILE/WEBSITEENGLPROPOSALFINAL.pdf
HSL3808
Cohen D, Hoeller K.
Screening for depression: preventive medicine or telemarketing?
Ethical Hum Sci Serv 2003 Spr;5:(1):3-6
HSL4809
Carr DM.
Pfizer's epidemic: a need for international regulation of human experimentation in developing countries.
Case West Reserve J Int Law 2003 Win;35:(1):15-53
HSL4907
McCabe AR.
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev 2003;36:(3):787-819
HSL5100
Breslow LH.
The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Harvard J Legis 2003 Win;40:(1):133-93
HSL5292
Rossman G, Rallis S.
Learning in the Field. An Introduction to Qualitative Research. 2nd Edn
Thousand Oaks: Sage Publications 2003
HSL5429
Gilovich T, Griffin D, Kahneman D.
Heuristics and biases: The psychology of intuitive judgment
Cambridge: Cambridge University Press 2003
HSL5591
Russell FM, Shann F, Curtis N, Mulholland K.
Evidence on the use of paracetamol in febrile children.
Bull World Health Organ 2003;81:(5):367-72
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862003000500011&lng=en&nrm=iso&tlng=en
HSL19335
Stell LK.
Physicians' conflicts of interest.
APA Newsl Philos Med 2003;3:(1):161-4
http://www.ncbi.nlm.nih.gov/pubmed/15115011
HSL7042
Eaton T. Fores Research Center
There Are No 'Chemical Imbalances'
2003
http://www.etfrc.com/ChemicalImbalances.htm
HSL7329
Pastakia S, Wertheimer AI.
Direct to consumer advertising of prescription vs. non-prescription drugs in the United States
Journal of Social and Administrative Pharmacy 2003;20:(6):197-203
HSL7331
Direct-to-consumer advertising and patients
WHO Drug Information 2003;17:(4):262-3
HSL7334
Gillat A.
Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Food Drug Law J 2003;58:(4):711-40
HSL7335
Shaeffer J.
Prescription drug advertising--should states regulate what is false and misleading?
Food Drug Law J 2003;58:(4):629-48
HSL7340
Levy S.
Will yuletide sales be torrid or tepid?
Drug Topics 2003;147:(23):86-89
HSL7341
Monaghan MS, Turner PD, Houghton BL, Markert RJ, Rich EC, .
Pharmacotherapy cost comparison among health professional students
American Journal of Pharmaceutical Education 2003;67:(3):
HSL7342
D'souza AO, Lively BT, Siganga W, Goodman MH.
Effects of direct-to-consumer advertising of prescription drugs: Perceptions of primary care physicians
Journal of Pharmaceutical Marketing and Management 2003;15:(3):61-75
HSL7343
Shah S, Holmes ER, Desselle SP.
The use of persuasion in print DTC advertisements of prescription drugs: A content analysis of leading consumer magazines from 1995-2000
Journal of Pharmaceutical Marketing and Management 2003;15:(3):23-43
HSL7344
Young HN.
'Look george, there's another one!' - The volume and characteristics of direct-to-consumer advertising in popular magazines
Journal of Pharmaceutical Marketing and Management 2003;15:(3):7-21
HSL7345
Patel RA, Ravnan MC.
Consumer-directed advertising of prescription medications
California Journal of Health System Pharmacy 2003;15:(6):15-18
HSL7346
Sax B.
Generic pain management continues to grow
Pharmacy Times 2003;69:(11):
HSL7352
Schwartz A.
Why generics will benefit from today's trends
US Pharmacist 2003;28:(11):3-4, 10-12
HSL7353
Santhouse A, Albano D.
Evaluation of Wyeth medical communications written responses and the impact on prescribing
Drug Information Journal 2003;37:(4):445-450
HSL7413
Peppin P, Carty E.
Signs of inequality: constructing disability in antidepressant drug advertising.
Health Law Journal 2003;11:(Special Ed):161-84
http://web.archive.org/web/20061010052207/http://www.law.ualberta.ca/centres/hli/pdfs/hlj/2003_Special/10_Peppin%20&%20Carty.pdf
HSL7448
Morin K, Morse LJ.
The ethics of pharmaceutical industry gift-giving: the role of a professional association.
Am J Bioeth 2003 Sum;3:(3):54-5
http://www.ncbi.nlm.nih.gov/pubmed/14594494
HSL7538
Kaitin KI, Cairns C.
The new drug approvals of 1999, 2000, and 2001: Drug development trends a decade after passage of the Prescription Drug User Fee Act of 1992
Drug Information Journal 2003;34:(7):357-371
HSL7540
Congress debates PBMs and medicare while FDA considers changes to DTC regulation
Formulary 2003;38:(11):657-658
HSL7541
Chi J.
Discount cards are serving as safety net to many seniors
Drug Topics 2003;147:(18):62
HSL7543
Kayne S.
New weapons in the fight against depression and breast cancer
New Zealand Pharmacy 2003;23:(11):21
HSL7544
Holmes ER, Desselle SP.
The prevalence of informational appeals in direct-to-consumer advertisements of prescription drugs among leading consumer magazines
Journal of Social and Administrative Pharmacy 2003;20:(4):132-141
HSL7547
Thompson A.
Patent expiries - How should they affect prescribing advice?
Pharmaceutical Journal 2003;271:(7272):587-589
HSL7548
McNaughton EL, Goodridge CM.
The Canadian approach to freedom of expression and the regulation of food and drug advertising.
Food Drug Law J 2003;58:(3):521-36
HSL7549
Blackwell AE, Beck JM
Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: Avoiding a pyrrhic victory
Food and Drug Law Journal 2003;58:(3):439-462
HSL7550
Evans GW, Friede AI
The Food and Drug Administration's regulation of prescription drug manufacturer speech: a First Amendment analysis.
Food Drug Law J. 2003;58:(3):365-437
HSL7552
Kahan JS, Shapiro JK.
The First Amendment and the Food and Drug Administration's regulation of labeling and advertising: three proposed reforms.
Food Drug Law J 2003;58:(3):353-64
HSL7554
Gilhooley M.
The Supreme Court checks out drug promotion restrictions.
Food Drug Law J 2003;58:(3):347-52
HSL7555
Gibbs JN, Ferrari PL, Murphy AM;
Ripe for revision: Reassessing the constitutionality of Food and Drug Administration restrictions on protected speech
Food and Drug Law Journal 2003;58:(3):331-345
HSL7557
Waxman HA.
A history of adverse drug experiences: Congress had ample evidence to support restrictions on the promotion of prescription drugs.
Food Drug Law J 2003;58:(3):299-312
HSL7558
Wechsler J.
Regulators and legislators address pharmaceutical rules and coverage - FDA offers new policies to relate enforcement to product risk
Formulary 2003;38:(10):606-7
HSL7564
Weems LK.
Importation and re-importation of prescription drugs: So what can we do about it?
Florida Pharmacy Today 2003;68:(9):18
HSL7566
Casteuble T.
HDMA Foundation report surveys industry's barcode readiness
HealthCare Distributor 2003;55:(4):15,17
HSL7606
Field RI.
Maine's plan to lower drug costs for the uninsured passes a major legal test
P and T 2003;28:(9):593
HSL7607
Tsai AC.
Policies to regulate gifts to physicians from industry
JAMA 2003;290:(13):1776
HSL7608
Tatchell M.
Free trade and the PBS
Pharmacy Review 2003;27:(3):21-22
HSL7609
Trading in our health system?
Pharmacy Review 2003;27:(3):19-21
HSL7610
Strict controls on advertising
Pharmacy Review 2003;27:(3):14, 19
HSL7611
Free rein for drug ads?
Consumer Reports 2003;68:(2):33-37
HSL7612
Koopmanschap MA, Rutten FF.
The drug budget silo mentality: The Dutch case
Value in Health 2003;6:(4):46-51
HSL7613
Hurley D.
Federal guidance
Pharmacy Practice News 2003;30:(7):
HSL7614
McCue MT.
The rock meets the hard place on drug prices and research
Managed Healthcare Executive 2003;13:(8):1
HSL7615
Franquesa N.
APS: additional value in the pharmacy?
Farmaceutico El 2003;(295):66,68,70,72,
HSL7616
Johanson V.
The Pan aftermath - where to from here?
Australian Journal of Pharmacy 2003;84:(1001):666-7
HSL7617
Moffitt CM, MacLean EA, Noris-sullivan V.
Helping seniors understand the healthcare system: A pharmacist directed educational series
ASHP Midyear Clinical Meeting 2003;
HSL7618
Drug advertising helps patients
Michigan Pharmacist 2003;41:(4):39
HSL7619
Tsang JP.
Hospital to home
Pharmaceutical Executive 2003;23:(7):84,86,88,90,92
HSL7620
Ho J.
Extending the product lifeline
Pharmaceutical Executive 2003;23:(7):70,72,74,76
HSL7621
Schreiber C.
The pivotal prescribers
Pharmaceutical Executive 2003;23:(7):62,64,66,68
HSL7622
Keeling P, Meade P.
How to make Rx-Dx alliances
Pharmaceutical Executive 2003;23:(7):48,50,52,54,56,58,60
HSL7623
Wechsler J.
The push for generics challenges manufacturers
Pharmaceutical Technology 2003;27:(7):26,28,30,32,34
HSL7624
Gaughan D.
Deficiencies observed during inspection
Irish Pharmacy Journal 2003;81:(5):208-210
HSL7626
Direct-to-consumer drug advertising: survey results
WHO Drug Information 2003;17:(1):15
HSL7630
Tatchell M.
Controlling drug expenditure in Europe
Pharmacy Review 2003;27:(1):28-9
HSL7631
Murawski MM, Mychaskiw MA, Surdej J.
Exploration of the relationship between health-related quality of life and the price of pharmaceutical products
Drug Information Journal 2003;37:(2):221-231
HSL7632
Vos LO.
Bring in the reinforcements
Pharmaceutical Executive 2003;23:(5):82-83
HSL7633
A forlorn end to the PIIP scheme?
Australian Journal of Pharmacy 2003;84:(998):348
HSL7634
Pal S.
More time needed for drug approvals
US Pharmacist 2003;28:(5):12, 15
HSL7635
Tarnoff S, Kowalski G, Bauer B.
Neglected prescribers
Pharmaceutical Executive 2003;23:(5):24,26,28
HSL7636
Perper E.
3-D marketing
Pharmaceutical Executive 2003;23:(5):138,140,142,144
HSL7637
Frank RG.
Perspective - Government commitment and regulation of prescription drugs
Health Affairs 2003;22:(3):46-48
HSL7638
DTC ad battle heals up
Pharmaceutical Executive 2003;23:(5):22
HSL7639
Miller J.
Bar code requirement would lead to adoption of efficient technology
Managed Healthcare Executive 2003;13:(5):42, 43, 45
HSL7642
Kalb PE, Dunlop KO, McEnroe DC, Stein SD.
Direct-to-consumer marketing: the Food and Drug Administration is not alone.
Food Drug Law J 2003;58:(1):25-33
HSL7643
Rao DA, Srinivas S.
OTC status for prescription drugs
Pharma Times 2003;35:(2):17-18
HSL7645
Waltz JA.
CMS report analyzes factors affecting the marketing of prescription drugs
Drug Benefit Trends 2003;15:(3):23-24,27
HSL7646
Fridman GA, Zimerman CA, Bregni C.
Consumption of antidepressant and anxiolytic drugs in Argentina in 1998
Ars Pharmaceutica 2003;43:(1-3):5-12
HSL7647
Barlas S.
Some drug ads don't "ad" up
P and T 2003;28:(1):19
HSL7648
Novelli WD.
Shake hands on Rx drugs for Medicare
Pharmaceutical Executive 2003;23:(2):18, 20
HSL7649
New obstacles slow efforts to speed generics to market
Drug Benefit Trends 2003;15:(2):16-17
HSL7651
Trimble LT, Ashby DM, Geize SB, Thomasset KB.
Cost-benefit analysis of indigent care programs for inpatients in a large academic medical center
ASHP Summer Meeting 2003;60:
HSL7653
Report criticizes FDA's oversight of DTC ads
American Journal of Health System Pharmacy 2003;60:(2):122,126
HSL7841
Millenson M
Getting Doctors to Say Yes to Drugs: The Cost and Quality Impact of Drug Company Marketing to Physicians
: Blue Cross and Blue Shield Association 2003
http://web.archive.org/web/20071026063406/http://www.bcbs.com/betterknowledge/cost/Drug_Co_Marketing_Report.pdf
HSL7865
Flynn FJ.
What have you done for me lately? Temporal adjustments to favor evaluations.
Organizational Behavior and Human Decision Processes 2003;91:(1):38-50
http://www.francisflynn.com/papers/WhatHaveYouDoneForMeLately.pdf
HSL19378
Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group.
Evaluating non-randomised intervention studies.
Health Technol Assess 2003;7:(27):iii-x,
http://www.hta.ac.uk/execsumm/summ727.htm
HSL9703
Wechsler J.
Drug pricing concerns shape policy decisions
Pharmaceutical Technology Europe 2003;15:(12):22-24
HSL9704
Albedo A.
One step further in EU medicine lobster quadrille
Pharmaceutical Technology Europe 2003;15:(11):12-17
HSL9738
Backman J.
Use of antidepressants in deliberate self-poisoning - Psychiatric diagnoses and drugs used between 1987 and 1997 in Lund, Sweden
Social Psychiatry and Psychiatric Epidemiology 2003;38:(12):684-689
http://link.springer-ny.com
Page 151 of 206 pages ‹ First < 149 150 151 152 153 > Last ›
